Adaptive Biotechnologies Current Cash

Adaptive Biotechnologies (ADPT) currently reports a current cash of $170M as of June 2026. That compares with $43M in the prior-year period — up 293.6% year over year. Use the charts on this page to explore Adaptive Biotechnologies's current cash history and peer comparisons.

Adaptive Biotechnologies's current cash increased from $43M to $170M — a 293.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptive Biotechnologies reported $170M in current cash as of June 2026. That compares with $43M in the prior-year period — up 293.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $170M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptive Biotechnologies, and consider following ADPT for alerts when major investors trade the stock.

Adaptive Biotechnologies is classified in the Healthcare sector. On current cash, it currently shows $170M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADPT with unrelated industries.